

March 3, 2015



## Titan Pharmaceuticals to Present at 27th Annual ROTH Conference

SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 03/03/15 -- [Titan Pharmaceuticals, Inc.](#) (OTCBB: TTNP), a specialty pharmaceutical company developing proprietary therapeutics for the treatment of select chronic diseases utilizing its ProNeura™ long-term drug delivery technology, announced today that Titan President Sunil Bhonsle will present at the 27<sup>th</sup> annual ROTH Conference on Monday, March 9 at 9:30 a.m. PT at The Ritz-Carlton in Laguna Niguel, Calif.

Mr. Bhonsle will review progress of the Phase 3 development program for Probuphine® for the maintenance treatment of opioid dependence and the potential re-submission of the Probuphine New Drug Application (NDA). He will also provide an overview of the company's ProNeura for Parkinson's disease program and key company milestones for 2015. The presentation will be available as a live and archived webcast at <http://wsw.com/webcast/roth29/ttnp>. The replay will be available for 90 days following the live broadcast. Interested parties may also access the webcast from the Titan website at [www.titanpharm.com](http://www.titanpharm.com).

### **About Titan Pharmaceuticals**

Titan Pharmaceuticals Inc. (OTCBB: TTNP), based in South San Francisco, CA, is a specialty pharmaceutical company developing proprietary therapeutics primarily for the treatment of serious medical disorders. The company's lead product candidate is Probuphine®, a novel and long-acting formulation of buprenorphine for the long-term maintenance treatment of opioid dependence. Probuphine employs Titan's proprietary drug delivery system ProNeura™, which is capable of delivering sustained, consistent levels of medication for six months or longer. Titan has granted North American commercial rights for Probuphine to Braeburn Pharmaceuticals. If approved, Probuphine would be the first and only commercialized treatment of opioid dependence to provide continuous, around-the-clock blood levels of buprenorphine for six months following a single procedure. The ProNeura technology has the potential to be used in developing products for treating other chronic conditions, such as Parkinson's disease, where maintaining consistent blood levels of a dopamine agonist may benefit the patient and improve medical outcomes. For more information about Titan, please visit [www.titanpharm.com](http://www.titanpharm.com).

*This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our product development programs and any other statements that are not historical facts. Such statements involve risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from management's current expectations include those risks and*

*uncertainties relating to the regulatory approval process, the development, testing, production and marketing of our drug candidates, patent and intellectual property matters and strategic agreements and relationships. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.*

**CONTACT:**

Titan Pharmaceuticals, Inc.  
Sunil Bhonsle  
650-244-4990  
President

**Media**

Susan Thomas  
619-540-9195  
[stthomas@titanpharm.com](mailto:stthomas@titanpharm.com)

Source: Titan Pharmaceuticals, Inc.